Prader-Willi Syndrome (PWS) Market is a rare genetic disorder that affects multiple systems in the body. The PWS market is currently experiencing significant growth, driven by increasing awareness, improved diagnosis, and the development of new therapies. This article provides an overview of the current market landscape, focusing on key trends, challenges, and opportunities.

The Prader-Willi Syndrome (PWS) market is estimated to be valued at USD 0.98 Bn in 2025 and is expected to reach USD 1.59 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.

Key Takeaways

The major players operating in the Prader-Willi Syndrome (PWS) market include

Soleno Therapeutics,

Harmony Biosciences,

Pfizer,

Novo Nordisk,

Sandoz,

ACADIA Pharmaceuticals,

Aardvark Therapeutics,

Gedeon Richter,

Palobiofarma,

ConSynance Therapeutics.

The PWS market is characterized by a high unmet medical need. Until recently, treatment options were primarily limited to managing the symptoms of the syndrome, such as growth hormone therapy for growth deficiency and behavioral interventions for hyperphagia and other behavioral issues. However, the approval of new drugs specifically targeting hyperphagia, the insatiable hunger that is a hallmark of PWS, has marked a significant turning point in the market. These new therapies are expected to improve the quality of life for PWS patients and drive market growth.

Get More Insight On : Prader-Willi Syndrome (PWS) Market

Get this Report in Japanese Language: プラダーウィリ症候群（PWS）市場-

Get this Report in Korean Language: 프라더윌리증후군(PWS)시장